SanReno Therapeutics

👥 5 employees💰 Last funded Jan 2022
Biotechnology Research🌐 sanreno.com
Website LinkedIn
Founded in December 2021, SanReno Therapeutics is a clinical-stage biotech focused on kidney diseases and related therapeutic areas. SanReno’s founding investors and partners including Chinook Therapeutics, a leading player in kidney diseases, as well as Pivotal bioVenture Partners China and Frazier Healthcare Partners, both world renown life-science investors. SanReno is committed to the research and development, production and commercialization of drugs in kidney diseases and related therapeutic areas, looks forward to providing innovative clinical solutions to prolong the lives of patients and create a better quality of living for them. Currently, SanReno holds two core assets in the Greater China area and Singapore, including atrasentan (Phase III) and BION-1301 (Phase II).
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in SanReno Therapeutics?
SanReno Therapeutics has 1 investors on record on gritt.io.
When did SanReno Therapeutics last raise funding?
The most recent investment in SanReno Therapeutics recorded on gritt.io was in January 2022.
What industry is SanReno Therapeutics in?
SanReno Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.